RxParadigm’s Tungsten+PLUS technology is a purpose-built, enterprise-grade platform designed to operationalize Medicare Maximum Fair Price (MFP) effectuation and 340B rebate claims adjudication at scale. The platform, which serves as a neutral clearinghouse rather than being controlled by either drug manufacturers or covered entities, delivers end-to-end execution across MFP implementation, claims reconciliation, and documented, good-faith dispute resolution, providing manufacturers, covered entities, and pharmacies with a single, neutral infrastructure to manage compliance, reduce financial exposure, and ensure disciplined execution across the full claim’s lifecycle.

This report provides an early, execution-focused assessment of Medicare Maximum Fair Price (MFP) implementation during the first 30 days following the Inflation Reduction Act’s effective date. January exposed fundamental operational stress points across the 340B ecosystem. Although the 340B Rebate Model Pilot was scheduled to launch on January 1, 2026, its suspension by the U.S. District Court for the District of Maine halted implementation, leaving manufacturers and covered entities to navigate unresolved rebate mechanics, inconsistent data-validation standards, and fragmented operational workflows at scale. Read More >